Evidence map›Paper›PMID 22666347›Full record

ArticlePloS one2012

Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo.

Torsten Rülker, Luzie Voß, Philippe Thullier, Lyn M O' Brien, Thibaut Pelat, Stuart D Perkins, Claudia Langermann, Thomas Schirrmann, Stefan Dübel, Hans-Jürgen Marschall and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Demonstration ofJournal of virology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Torsten RülkerTechnische Universität Braunschweig, Institut für Biochemie und Biotechnologie, Braunschweig, Germany.
Luzie Voß
Philippe Thullier
Lyn M O' Brien
Thibaut Pelat
Stuart D Perkins
Claudia Langermann
Thomas Schirrmann
Stefan Dübel
Hans-Jürgen Marschall
Michael Hust
Birgit Hülseweh
Technische Universität Braunschweig · DEWehrwissenschaftliche Institut für Schutztechnologien · DEDefence Science and Technology Laboratory · GBService de Santé des Armées · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Venezuelan equine encephalitis virus (VEEV) belongs to the Alphavirus genus and several species of this family are pathogenic to humans. The viruses are classified as potential agents of biological warfare and terrorism and sensitive detection as well as effective prophylaxis and antiviral therapies are required.In this work, we describe the isolation of the anti-VEEV single chain Fragment variable (scFv), ToR67-3B4, from a non-human primate (NHP) antibody gene library. We report its recloning into the bivalent scFv-Fc format and further immunological and biochemical characterisation.The scFv-Fc ToR67-3B4 recognised viable as well as formalin and ß-propionolactone (ß-Pl) inactivated virus particles and could be applied for immunoblot analysis of VEEV proteins and immuno-histochemistry of VEEV infected cells. It detected specifically the viral E1 envelope protein of VEEV but did not react with reduced viral glycoprotein preparations suggesting that recognition depends upon conformational epitopes. The recombinant antibody was able to detect multiple VEEV subtypes and displayed only marginal cross-reactivity to other Alphavirus species except for EEEV. In addition, the scFv-Fc fusion described here might be of therapeutic use since it successfully inactivated VEEV in a murine disease model. When the recombinant antibody was administered 6 hours post challenge, 80% to 100% of mice survived lethal VEEV IA/B or IE infection. Forty to sixty percent of mice survived when scFv-Fc ToR67-3B4 was applied 6 hours post challenge with VEEV subtypes II and former IIIA. In combination with E2-neutralising antibodies the NHP antibody isolated here could significantly improve passive protection as well as generic therapy of VEE.

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralCloning, MolecularEncephalitis Virus, Venezuelan EquineGene LibraryGenetic VectorsHumansImmunization, PassiveMacaca fascicularisMaleMiceMice, Inbred BALB CRecombinant Fusion ProteinsSequence AnalysisSingle-Chain AntibodiesAntibodies, NeutralizingAntibodies, ViralRecombinant Fusion ProteinsSingle-Chain Antibodies

Identifiers

PMID22666347
PMCPMC3364240
OpenAlexW2059382404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.